Expression of Bcl-2 in olfactory neuroblastoma and its association with chemotherapy and survival

Otolaryngology - Head and Neck Surgery

Volumn 139, Issue 5, 2008, Pages 708-712

  Kim, Jeong Whun ^a   Kong, Il Gyu ^a   Lee, Chul Hee ^a   Kim, Dong Young ^a   Rhee, Chae Seo ^a   Min, Yang Gi ^a   Kim, Chul Woo ^a   Chung, Jin Haeng ^a  

^a Seoul National University Bundang Hospital   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; ETOPOSIDE; IFOSFAMIDE; PROTEIN BCL 2; PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; ESTHESIONEUROBLASTOMA; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; IN SITU HYBRIDIZATION; MALE; ONCOGENE C MYB; PROGNOSIS; PROTEIN EXPRESSION; TREATMENT RESPONSE;

ADULT; AGED; ANTINEOPLASTIC AGENTS; COHORT STUDIES; ESTHESIONEUROBLASTOMA, OLFACTORY; FEMALE; HUMANS; MALE; MIDDLE AGED; NASAL CAVITY; NEOADJUVANT THERAPY; NOSE NEOPLASMS; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-BCL-2; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 54549116924     PISSN: 01945998     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.otohns.2008.03.011     Document Type: Article

References (25)

1. Kadish S., Goodman M., and Wang C.C. Olfactory neuroblastoma: a clinical analysis of 17 cases. Cancer 37 (1976) 1571-1576
2. Resto V.A., Eisele D.W., Forastiere A., et al. Esthesioneuroblastoma: the Johns Hopkins experience. Head Neck 22 (2000) 550-558
3. Chao K.S., Kaplan C., Simpson J.R., et al. Esthesioneuroblastoma: the impact of treatment modality. Head Neck 23 (2001) 749-757
4. Constantinidis J., Steinhart H., Koch M., et al. Olfactory neuroblastoma: the University of Erlangen-Nuremberg experience 1975-2000. Otolaryngol Head Neck Surg 130 (2004) 567-574
5. Krajewski S., Tanaka S., Takayama S., et al. Investigation of the subcellular distribution of the bcl-2 oncoprotein: residence in the nuclear envelope, endoplasmic reticulum, and outer mitochondrial membranes. Cancer Res 53 (1993) 4701-4714
6. Violette S., Poulain L., Dussaulx E., et al. Resistance of colon cancer cells to long-term 5-fluorouracil exposure is correlated to the relative level of Bcl-2 and Bcl-X(L) in addition to Bax and p53 status. Int J Cancer 98 (2002) 498-504
7. Huang Z. Bcl-2 family proteins as targets for anticancer drug design. Oncogene 19 (2000) 6627-6631
8. Shinoura N., Yoshida Y., Nishimura M., et al. Expression level of Bcl-2 determines anti- or proapoptotic function. Cancer Res 59 (1999) 4119-4128
9. Dole M., Nunez G., Merchant A.K., et al. Bcl-2 inhibits chemotherapy-induced apoptosis in neuroblastoma. Cancer Res 54 (1994) 3253-3259
10. Campos L., Rouault J.P., Sabido O., et al. High expression of bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy. Blood 81 (1993) 3091-3096
11. Lagarde S.M., Ten Kate F.J., Richel D.J., et al. Molecular prognostic factors in adenocarcinoma of the esophagus and gastroesophageal junction. Ann Surg Oncol 14 (2007) 977-991
12. Zhu C.Q., Shih W., Ling C.H., et al. Immunohistochemical markers of prognosis in non-small cell lung cancer: a review and proposal for a multiphase approach to marker evaluation. J Clin Pathol 59 (2006) 790-800
13. Sasaki M., Kumazaki T., Tanimoto K., et al. Bcl-2 in cancer and normal tissue cells as a prediction marker of response to 5-fluorouracil. Int J Oncol 22 (2003) 181-186
14. Tas F., Duranyildiz D., Oguz H., et al. Serum vascular endothelial growth factor (VEGF) and bcl-2 levels in advanced stage non-small cell lung cancer. Cancer Invest 24 (2006) 576-580
15. Chabay P., Pesce P., De Matteo E., et al. No Influence of bcl-2, p53, and p21waf1 protein expression on the outcome of pediatric Hodgkin lymphomas. J Pediatr Hematol Oncol 28 (2006) 552-558
16. Scott N., Hale A., Deakin M., et al. A histopathological assessment of the response of rectal adenocarcinoma to combination chemo-radiotherapy: relationship to apoptotic activity, p53 and bcl-2 expression. Eur J Surg Oncol 24 (1998) 169-173
17. Devaney K., Wenig B.M., and Abbondanzo S.L. Olfactory neuroblastoma and other round cell lesions of the sinonasal region. Mod Pathol 9 (1996) 658-663
18. Miyashita T., and Reed J.C. Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line. Blood 81 (1993) 151-157
19. Walch C., Stammberger H., Anderhuber W., et al. The minimally invasive approach to olfactory neuroblastoma: combined endoscopic and stereotactic treatment. Laryngoscope 110 (2000) 635-640
20. Casiano R.R., Numa W.A., and Falquez A.M. Endoscopic resection of esthesioneuroblastoma. Am J Rhinol 15 (2001) 271-279
21. Dave S.P., Bared A., Casiano R.R., et al. Surgical outcomes and safety of transnasal endoscopic resection for anterior skull tumors. Otolaryngol Head Neck Surg 136 (2007) 920-927
22. Hwang S.K., Paek S.H., Kim D.G., et al. Olfactory neuroblastomas: survival rate and prognostic factor. J Neurooncol 59 (2002) 217-226
23. Dulguerov P., and Calcaterra T. Esthesioneuroblastoma: the UCLA experience 1970-1990. Laryngoscope 102 (1992) 843-849
24. Levine P.A., Debo R.F., Meredith S.D., et al. Craniofacial resection at the University of Virginia (1976-1992): survival analysis. Head Neck 16 (1994) 574-577
25. Diaz Jr. E.M., Johnigan III R.H., Pero C., et al. Olfactory neuroblastoma: the 22-year experience at one comprehensive cancer center. Head Neck 27 (2005) 138-149